Lyra Therapeutics (LYRA) Misses Q2 EPS by 534c

Lyra Therapeutics (NASDAQ: LYRA) reported Q2 EPS of ($5.51), $5.34 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $183 thousand versus the consensus estimate of $242 thousand.

For earnings history and earnings-related data on Lyra Therapeutics (LYRA) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• ICICI Securities Resumes Dalmia Bharat Ltd (DALBHARA:IN) at Add (2)
• UBS Upgrades Apollo Tyres (APTY:IN) to Buy